Ajanta Pharma is currently trading around the ₹2800 mark, which has acted as a strong resistance zone over the past few months. The stock has tested this level 4 to 5 times, indicating significant supply pressure and trader interest at this price point.
At this stage, Ajanta Pharma stands at a crucial inflection point:
📈 Bullish Scenario:
A clean breakout above ₹2800, especially with volume confirmation, could potentially lead to a 10% upside in the near term, with scope for a 20% rally if momentum sustains.
📉 Bearish Scenario:
However, if the stock fails to break through and faces rejection again, we might see a pullback of around 10%, as traders book profits or short near resistance.
This setup presents a high-reward trade opportunity with a well-defined risk level, making it a good candidate to keep on your watchlist.
Disclaimer:
This post is for educational and informational purposes only. I am not a SEBI-registered investment advisor or research analyst. Please do your own research or consult a certified financial advisor before making any investment decisions.
At this stage, Ajanta Pharma stands at a crucial inflection point:
📈 Bullish Scenario:
A clean breakout above ₹2800, especially with volume confirmation, could potentially lead to a 10% upside in the near term, with scope for a 20% rally if momentum sustains.
📉 Bearish Scenario:
However, if the stock fails to break through and faces rejection again, we might see a pullback of around 10%, as traders book profits or short near resistance.
This setup presents a high-reward trade opportunity with a well-defined risk level, making it a good candidate to keep on your watchlist.
Disclaimer:
This post is for educational and informational purposes only. I am not a SEBI-registered investment advisor or research analyst. Please do your own research or consult a certified financial advisor before making any investment decisions.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。